Spero Therapeutics’ (SPRO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday,Benzinga reports.

Several other research firms also recently issued reports on SPRO. HC Wainwright dropped their price target on shares of Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, November 4th. TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th.

Spero Therapeutics Price Performance

SPRO opened at $1.24 on Friday. Spero Therapeutics has a 1 year low of $1.01 and a 1 year high of $1.89. The business has a fifty day simple moving average of $1.30 and a 200 day simple moving average of $1.37. The company has a market capitalization of $66.83 million, a PE ratio of 3.70 and a beta of 0.63.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SPRO. Acadian Asset Management LLC increased its position in Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after buying an additional 418,742 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Spero Therapeutics during the first quarter valued at $31,000. Vanguard Group Inc. raised its position in shares of Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Finally, Murchinson Ltd. increased its holdings in shares of Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares in the last quarter. 25.60% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.